4D Molecular Therapeutics (FDMT) Equity Ratio (2019 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Equity Ratio for 7 consecutive years, with 0.87 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 4.93% to 0.87 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.87, a 4.93% decrease, with the full-year FY2024 number at 0.91, up 0.61% from a year prior.
- Equity Ratio was 0.87 for Q3 2025 at 4D Molecular Therapeutics, down from 0.89 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2024 to a low of 0.87 in Q3 2025.
- A 5-year average of 0.91 and a median of 0.91 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: rose 6.43% in 2024, then dropped 6.34% in 2025.
- 4D Molecular Therapeutics' Equity Ratio stood at 0.9 in 2021, then decreased by 2.13% to 0.88 in 2022, then increased by 2.51% to 0.91 in 2023, then increased by 0.61% to 0.91 in 2024, then dropped by 4.49% to 0.87 in 2025.
- Per Business Quant, the three most recent readings for FDMT's Equity Ratio are 0.87 (Q3 2025), 0.89 (Q2 2025), and 0.91 (Q1 2025).